- 2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market.
- Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine trials.
- A low interest rate macro environment, scientific advances, and M&A to boost biotech valuations.
- Regulatory noise around drug-pricing to increase in the second-half, though no meaningful change to occur this year.
- Fundamentals and technical appear aligned for 2021 to be a strong year for biotechs, with a couple of potential catalysts expected in January.
For further details see:
Biotech Bonanza: 2021 Outlook In A Post-Pandemic Year